Multi-targeted anti-inflammatory drugs for the treatment of neurological disorders
Austin Lui1
Omar Alzayat1
Timothy Do1
David Perekopskiy1
Meghan Gann1
Taiseer Saad Elgokhy1
Jie Gao2
DaZhi Liu1
1.Department of Neurology,University of California at Davis,Sacramento,CA,USA2.Department of Neuroscience,The Ohio State University,Columbus,OH,USA
摘要：Inflammation and kinase pathophysiology in neurological disorders: Inflammation is one of the common features of various acute and degenerative neurological disorders, such as stroke, traumatic brain injury (TBI), Alzheimer's disease (AD), Parkinson's disease (PD), and others. The inflammatory responses are manifested as the synthesis of inflammation mediators, recruitment of leukocytes, and other secondary injuries. Compelling evidence shows that a large number of inflammation mediators (e.g., thrombin, reactive oxygen species, cytokines, chemokines, and other molecules) are implicated in the pathophysiological processes in neurological disorders (Liu and Ander, 2012) (Figure 1). These increased inflammation mediators stimulate their downstream transmembrane receptors (e.g., protease-activated receptors, cytokine receptors, and others), and further activate the intracellular downstream effector kinases, such as Src family kinase, Rho-associated protein kinase, Jun N-terminal kinase, extracellular signal-regulated kinase, cyclin-dependent kinase (CDK), and others (Liu and Ander, 2012) (Figure 1). Aside from overlapping in different neurological disorders, numerous inflammatory molecules and multiple kinase-involved signaling pathways can be linked to a single neurological disorder such as AD (Heneka et al., 2015). Because of their pivot roles in the process of inflammation, kinases have been regarded as anti-inflammatory targets to improve outcomes of neurological disorders.
机标关键词：antidisordersdrugsinflammatorymulti-targetedneurologicaltreatment
论文发表日期：2023-04-28
在线出版日期：2025-08-15（本平台首次上网日期，不代表文献的发表时间）
页数：2( 805-806 )